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Rationale: Evidence indicates that histamine (HA)modulates learning andmemory in different types of behavioral
tasks; however, the exact nature of this modulation and its mechanisms are controversial. Furthermore, emotions
are able to inﬂuence memory processing in a crucial way through the involvement of the amygdala. Our research
aims to contribute to the neurobiological body of knowledge on acquisition and retrieval of emotional memory via
the histaminergic amygdaloid system in mice.
Objectives: The present study investigatedwhether exogenous HA infused into the amygdala differentially modu-
lates the anxiety- and fear-related memory of mice assessed by unconditioned and conditioned tasks.
Methods:Over two consecutive days, animals received bilateralmicroinjections of either vehicle orHA (0.1, 0.5 and
1.0 μg by 0.1 μl/side volume) into the amygdala before behavioral tests were performed. Mice were examined
under two paradigms: an exposure/re-exposure procedure in the elevated plus-maze (EPM) or in the inhibitory
avoidance (IA) with electric foot shock trials 1 and 2 and retention test (without foot shock).
Results: Pre-test intra-amygdala microinjection of 0.5 μg HA induced anxiolytic-like responses, but none of the
three doses interfered in mnemonic processing examined in the EPM. Concerning the IA task, step-through reten-
tion latencies increased in all groups compared with their respective trials, except in the animals microinjected
with 0.5 or 1.0 μg HA before the retention test. Thus, HA caused statistically signiﬁcant amnesia during the session
repeated 24 h after trainingwithout drugs. Retention latencywas notmodiﬁed bymicroinjections of HA both pre-
trial and pre-test or by pre-trial infusion in mice subjected to IA.
Conclusions: Our data indicate that the amygdaloid histaminergic system could modulate anxiety-related behav-
iors in the EPM and impair the retrieval process in fear conditioning with a strong aversive stimulus. These results
contribute further evidence of the distinct histaminergic inﬂuence on different emotional pathways.© 2015 Elsevier Inc. All rights reserved.1. Introduction
The histaminergic neural system (HNS) is composed of neuronal
groupings in the brain of phylogenetically lower vertebrates and higher
mammals that cover almost all areas of the central nervous system
(CNS) (Haas and Panula, 2003). Neurons that synthesize histaminevioral inhibition system; BLA,
s of the amygdala; CNS, central
ne; HNS, histaminergic neural
tricular; i.p., intraperitoneally;
sed arm entries; TE, total arm
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fscar.br (R. Mattioli).(HA) are conﬁned to the tuberomamillary nucleus of the posterior
hypothalamus (Brown et al., 2001; Watanabe et al., 1984). Moderate
densities of these histaminergic ﬁbers supply the amygdaloid complex
(Haas et al., 2008; Watanabe et al., 1984), which is a set of nuclei with
functional and anatomical distinction (Ehrlish et al., 2009) besides
substantial HA receptor expression.
The basolateral nucleus (BLA) and central nucleus (CEA) of the
amygdala are described as two functional subdivisions regarding fear
conditioning (Maren, 2003; Orsini andMaren, 2012). The BLA is activat-
ed during emotional experiences that the individual perceives as anxi-
ety, fear, stress and rage, together with cortical and subcortical afferent
pathways (Rogan and LeDoux, 1996). The CEA neurons extensively
project to extrinsic structures, such as the hypothalamus and the
periaqueductal gray matter (Davis et al., 1994; Sah et al., 2003); instead
of being a passive retransmission area from fear generating structures,
the CEA is involved in the origin of aversive memory (Orsini and
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processing and plasticity underlying fear conditioning (Maren, 2008).
According to Panksepp (2011), one of the major emotional operat-
ing systems genetically deﬁned and experientially reﬁned is the fear/
anxiety system. These two different states could be ethologically sepa-
rated according to the defense pattern in rodents, which in turn
depends on the physical distance from a threat (Blanchard et al.,
1993; Davis et al., 2009). While fear is an emotion activated by immi-
nent and real threat, anxiety is an entity aroused by distal and potential
danger associated with an extended state of apprehension (Davis et al.,
2009). Gross and Canteras' study (2012) supported the existence of
distinct fear pathways that are specialized to address threats of an in-
nate or learned nature, with the amygdala gathering multiple afferent
inputs and distributing these inputs to their respective efferent path-
ways. Furthermore, the excitability of the amygdaloid circuitry can be
regulated by strategies, e.g., the pharmacological approach with benzo-
diazepines, resulting in anxiety-reducing effects and enhancing the
critical involvement of the amygdala in anxiety (Davis et al., 1994).
The physiologicalmechanisms underlying experience-driven changes
in neural function that characterize fear conditioning could overlap with
learning and memory processes (Rogan and LeDoux, 1996; McGaugh,
2004). Regarding the elevated plus-maze, a classical model to detect
anxiety-like behavior, a prior maze trial can impact the emotional reac-
tion of rodents due to the acquisition of a phobic response to the unpro-
tected areas (Holmes and Rodgers, 1998). Known as emotional memory,
these experiences with emotional valence are rapidly acquired and
enable organisms to address future threats as long lasting memory
(Rogan and LeDoux, 1996; Orsini and Maren, 2012). For instance, defen-
sive responses are exhibited by animals after an aversive stimulus, which
can be regulated by HA in the brain, among other neurotransmitters.
Histaminergic receptor stimulation activates a pre- and post-synaptic
transmitting chain implicated in neuronal plasticity and its functional
and structural concomitants (Dere et al., 2010).
The acquisition and retrieval of aversive memory conditioned to
taste in rats were evaluated after treatment with pyrilamine, an H1-
antagonist. Microinjection of pyrilamine into the magnocellular basal
nucleus impaired this aversive conditioning (Purón-Sierra et al.,
2010). Recent evidence suggests that disrupted HA signaling through
the H1-, H2- and H3-receptors may be an important key in cognitive
disorders (Panula and Nuutinen, 2013). In pre-clinical human research,
the HA level was shown to be reduced in the hippocampus, temporal
cortex and hypothalamus of patients with Alzheimer's disease, which
suggests that the degeneration of histaminergic neurons contributes
to the cognitive decline (Airaksinen et al., 1991). Thus, HA receptors in
the CNS must be studied as targets for therapeutic intervention
(Passani and Blandina, 2011).
Due to the important role of the amygdala in emotional behavior and
in memory modulation (Dere et al., 2010; Rogan and LeDoux, 1996),
and considering that the amygdaloid histaminergic system remains
unclear, the present study aims to further investigate HA function in
anxiety and/or fear circuitry. We investigated the effects of exogenous
HA injected into the amygdala on fear and anxiety-like behaviors, as
assessed by the inhibitory avoidance task and the elevated plus-maze,
respectively, as well as the emotional learning and memory of mice.
2. Material and methods
2.1. Animals
In total, 200 Swissmalemice (Musmusculus) aged from5 to 7weeks
from the bioterium of the Federal University of Sao Carlos (UFSCar)
were used for this experiment. Mice were kept in groups of 5 animals
in polycarbonate transparent cages (28 × 18 × 11 cm) at the bioterium
of the Laboratory of Neurosciences, UFSCar, until the mice reached
weights between 25 and 35 g. Animals cages were stored in a ventilated
rack in the same environment, with a temperature of 24± 1 °C, relativehumidity of 55± 5% and under a light/dark cycle of 12/12 h (light cycle
starting at 07:00 a.m.), which was automatically controlled. Water and
food were available to the mice ad libitum, except during the brief
testing periods. The experiments with naive mice were performed
during the light phase of the photoperiod (08:00 to 14:00) to minimize
the variability of the circadian inﬂuence.
The project was approved by the Ethics Committee on Animal Use
(CEUA), UFSCar, under protocol number 028/2011 and registration
number 018/2011. Additionally, the experimental procedures followed
the rules of the National Council for Animal Experimentation Control
(CONCEA), Brazil.
2.2. Behavioral tests
2.2.1. Experiment 1: effects of intra-amygdala HA microinjection on the
emotional memory of mice in the inhibitory avoidance task
2.2.1.1. Inhibitory avoidance task. Studies of the HA effects on inhibitory
avoidancewere performed byAlmeida and Izquierdo (1986) and exten-
sively described over recent years (Benetti and Izquierdo, 2013; Bonini
et al., 2011; Da Silva et al., 2006; Detrait et al., 2009). In the present
investigation, IA behavior was studied in a two-trial learning, step-
through situation (Fine et al., 1985; Page et al., 1991), which utilizes
the natural preference of rodents for dark environments due to their
photophobia (Detrait et al., 2009). A box (48 × 27 × 30 cm) composed
of acrylic plates consisted of two compartments: a bright compartment
(crystal colored, 456 lx luminosity, 24 × 13.5 × 15 cm) and a dark com-
partment (black colored, 24 × 13.5 × 15 cm),with a guillotine type door
(7 × 7 cm) in the middle of the divider wall. Stainless steel grids
(2.5 mm in diameter) were placed at 1-cm intervals (distance between
the centers of grids) on the ﬂoor to spread out the foot shock. A camera
was placed above the box and attached to a computer with software
that recorded the sessions (Surveillance System GV-600; GeoVision,
Inc.; Neihu District, Taipei, Taiwan).
Micewere left in the experimental room for 1 h before the beginning
of the procedure, and after that, each mouse was habituated to the
apparatus (Fig. 1a). Each animal was placed into the illuminated com-
partment facing the door, which was opened after 6 s, allowing its
entry into the dark compartment. Mice that required more than 100 s
to cross to the other side were eliminated from the experiment. The
door was closed when the animal crossed with its four paws to the
next compartment, and the mouse was taken from the dark compart-
ment into the home cage. After 30 min, the animal was microinjected
with HA or vehicle into the amygdala and singly placed in a home
cage for 5 min to minimize the restraining stress. Thereafter, trial 1
was carried out by ﬁrst placing the mouse in the bright compartment;
after 6 s, the door was opened and a foot shock (0.5 mA, 3 s) was trig-
gered immediately after the mouse's entry into the dark compartment.
Twenty seconds later, the animal was taken out of the apparatus and
returned to the home cage. A second trial (trial 2) was carried out
after a 2-min interval; the criterion for successful acquisition of avoid-
ance responses in mice was non-entry into the dark compartment for
a period of 120 s. Otherwise, the mouse got a second shock if it went
into the dark compartment during trial 2. Twenty-four hours after the
second trial, themicroinjection procedure was repeated and a retention
test to evaluate avoidance responsewas performed. As described above,
eachmousewas placed in the bright side and the doorwas opened after
6 s; latency to re-enter the dark compartment was recorded with a
maximum of 300 s. During the test, no electric shock was applied.
The apparatus was cleaned withwet cotton and 5% alcohol between
the tests. The step-through latencies for entries into the dark compart-
ment during trials 1 and 2 and the retention test were manually
measured by the experimenter using a stopwatch. One to four mice
per group reached up to 120 s of acquisition criteria during trial 2,
i.e., mice received only one shock; other mice (on average, 80% of the
total sample) received two shocks.
Fig. 1. Schematic representation of the experimental design for the [a] inhibitory avoidance task and [b] elevated plus maze (EPM). HA histamine; SAL saline.
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behavior and emotional memory of mice in the elevated plus-maze
2.2.2.1. Elevated plus-maze. EPMwas originally proposed for rats (Pellow
et al., 1985) and was later validated for Swiss mice, with some adapta-
tions (Lister, 1987). The test is widely employed to score the anxiety
level of rodents in a one-trial protocol (File, Mabbutt, Hitchcott, 1990;
Carobrez and Bertoglio, 2005) and to assess emotional learningunderly-
ing the exploratory behavior in a two-trial paradigm (Rodgers et al.,
1996; Dal-Cól et al., 2003; Bertoglio, Joca, Guimarães, 2006). The maze
used was composed of gray acrylic plates consisting of two open arms
(30 × 5.0 × 0.25 cm) and two closed arms with opaque walls
(30 × 5.0 × 15.25 cm), such that the open or closed armswere opposite
from each other. The armswere joined by a central platform (5 × 5 cm)
and elevated 38.5 cm from the ﬂoor by a support. The perimeter of the
open arms had a tiny border 0.25 cm in thickness.
A black curtain was placed around the EPM during the tests to avoid
possible environmental visual clues. The luminosity at the center of
the EPM was 48 lx. A camera was placed above the EPM and attached
to a computer with software to record the test (Surveillance System
GV-600; GeoVision, Inc.; Neihu District, Taipei, Taiwan).
During the ﬁrst testing day (T1), the mice were removed from the
animal house and left in the experimental room for 1 h before the test
(Fig. 1b). Each mouse was microinjected with HA or vehicle and singly
placed in a cage for 5 min to minimize the restraining stress. Subse-
quently, the animal was placed in the center of the EPM, facing one of
the open arms with 5 min of free exploration. Twenty-four hours later
(T2), the experimental procedure was repeated. The apparatus was
cleaned with 5% alcohol between the tests.
During the test, the following conventional measurements were
taken: the number of entries into the open (OAE) and enclosed (EAE)
arms, the total arm entries (TE), and the time spent in the open arms
(OAT). An entry was deﬁned as all four feet in one arm. All of these
parameters were measured by the experimenter using the software
X-Plo-Rat (Garcia et al., 2005) for behavioral records. The number of
entries and the time spent in the open armswere calculated in percent-
ages [%OAE= (entries into the open arms/total entries) × 100; %OAT=
(time spent in the open arms / 300 s) × 100]. Enclosed arm entries were
considered a measurement to infer locomotor activity. In T1, increases
in the percentage of open arm entries and in the percentage of time
spent in the open armswere interpreted to be indicative of potential an-
xiolytic activity (Cruz et al., 1994; Lister, 1987; Rodgers and Johnson,
1995). In T2, a decrease in these same measurements related to T1was interpreted to be indicative of learning and memory (Bertoglio
et al., 2006; Dál-Col et al., 2003).
2.3. Surgery
Mice were intraperitoneally (i.p.) anesthetized (injection volume:
1 ml/kg) with ketamine (50 mg/kg body weight) and xylazine
(5 mg/kg body weight) dissolved in sterile 0.9% saline solution. Subse-
quently, they were positioned in a stereotaxic frame to bilaterally
implant a 7-mm guide cannula (25-gauge guide) 1 mm over the amyg-
dala according to the stereotaxic atlas for themouse brain (Paxinos and
Franklin, 2001) using the following coordinates: 0.8mmposterior to the
bregma, ±2.7 mm lateral to the sagittal midline and 3.5 mm below the
skull surface. A screwwasﬁxed anterior to the bregma, and the two can-
nulae were ﬁxed with dental acrylic resin covering the mouse skull
(self-polymerizing acrylic and liquid acrylic JET, Artigos Odontológicos
Clássico Ltda., São Paulo, Brazil). Then, analgesic injection (ﬂunixine
meglumine, 2.5 mg/kg bodyweight) was intramuscularly administered
and dummy cannulae (7 mm, 33 gauge) were inserted in the guide
cannula to prevent blockage and contamination. Mice were allowed to
recover for 3–5 days.
2.4. Microinjection and treatment
After recovery from the surgery, eachmousewasmicroinjectedwith
HA or vehicle (saline, SAL) 5 min before the behavioral testing. For the
microinjection procedure, mice were gently restrained, the dummy
cannulae were removed, and a ﬁne needle (8 mm) was inserted into
each guide cannula 1.0mm longer than the guide end, allowing infusion
of the drug into the target area. The solution was slowly injected over
60 s with the needle connected through a polyethylene tube (PE-10)
to a 5.0-μl Hamilton syringe, keeping the injection unit in situ for a
further 60 s. A 0.1-μl injection of HA or vehicle was controlled by a
planned infusion pump (BI 2000, Insight Equipamentos Cientíﬁcos
Ltda., Ribeirão Preto, SP, Brazil).
Experiment 1 and Experiment 2 consisted of four groups for each
dose of HA (Table 1). Both experiments were performed during 2
consecutive days with the administration of drug or vehicle prior to
behavioral assessment of learning and retrieval, which are different
stages of the mnemonic process. Therefore, the experimental groups
were the following: control group (SAL–SAL); groups treated with HA
before T1/trial 1 (HA 0.1–SAL, HA 0.5–SAL and HA 1.0–SAL) and/or
before T2/retention test (HA–HA 0.1, HA–HA 0.5, HA–HA 1.0, SAL–HA
Table 1
Groups named according to histamine (HA) or vehicle (SAL) microinjection into the
amygdala before T1 and T2 in the EPM and before trial 1 and the retention test in the IA.
Numbers indicate the sample size for each experimental group.
Behavioral test Dose
EPMa IAb HA
0.1 μg
HA
0.5 μg
HA
1.0 μg
T1 T2 Trial 1 Test EPM IA EPM IA EPM IA
SAL–SAL SAL SAL SAL SAL 7 9 10 9 9 8
SAL–HA SAL HA SAL HA 9 10 9 10 7 8
HA–SAL HA SAL HA SAL 7 8 9 10 6 8
HA–HA HA HA HA HA 7 9 8 9 7 7
a EPM: elevated plus maze.
b IA: inhibitory avoidance.
Fig. 2. Photomicrograph [a] and schematic representation of coronal sections of the
mouse brain [b] showing bilateral microinjection sites into the amygdala (indicated
by arrows and black dots, respectively). Diagrams are adapted from Paxinos and
Franklin (2001). Rostral to caudal: 1.46, 1.70 and 1.82 mm posterior to the bregma.
AStr amygdalostriatal transition area; BLA basolateral amygdaloid nucleus, anterior
part; BLV basolateral amygdaloid nucleus, ventral part; BMA basomedial amygdaloid
nucleus, anterior part; BMP basomedial amygdaloid nucleus, posterior part; BSTIA
bed nucleus of the stria terminalis, intraamygdaloid division; CeC central amygdaloid
nucleus, capsular part; CeL central amygdaloid nucleus, lateral division; CPu caudate
putamen (striatum); DEn dorsal endopiriform nucleus; D3V dorsal 3rd ventricle;
ec external capsule; ic internal capsule; LaDL lateral amygdaloid nucleus, dorsolateral
part; LGP lateral globus pallidus; LaVL lateral amygdaloid nucleus, ventrolateral part;
LV lateral ventricle; st stria terminalis; VEn ventral endopiriform nucleus; 3V 3rd
ventricle.
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the ﬁrst day of testing in both experiments.
2.5. Drugs
The powder formof histamine dihydrochloride (SigmaChemical Co.,
St. Louis, Missouri, USA), 2-(4-imidazolyl) ethylamine dihydrochloride
[Mr(C5H9N3·2HCl) = 184.07 g/mol], an HA receptor (H1–H4) agonist,
were dissolved in sterile 0.9% saline solution to obtain three distinct
doses of 0.1, 0.5 and 1.0 μg (Moghaddam et al., 2008; Hasenörl et al.,
2001).
2.6. Histological analysis
After the behavioral assessment, allmicewere subjected to euthana-
sia with an overdose of anesthetic solution (triple the recommended
dose for xylazine and ketamine chloride dissolved in 0.9% saline
solution). Brains were removed and immersed in 10% formalin for at
least 3 days. Subsequently, the brains were immersed in 20% sucrose
solution for 24 h and in 30% sucrose solution for a further 24 h. There-
after, the brains were sliced into 80-μm-thick coronal sections on a
cryostat-microtome (ANCAP 300). The exact microinjection sites were
veriﬁed with an optic microscope (Olympus B202) and compared
with the stereotactic atlas of the mouse brain (Paxinos and Franklin,
2001). Data from animals with injection sites outside the amygdala
were excluded from the study.
2.7. Statistical analysis
Data are presented as the means ± standard error of the mean
(SEM). After Levene's test to conﬁrm the data homogeneity, three-
way repeated measures ANOVA was applied for the mice treated with
SAL or HA at its three doses in the IA and EPM. The three factors
analyzed were session (for IA data: trial 1 compared with trial 2; trial
1 or trial 2 compared with test; for EPM data: T1 compared with T2),
dose (comparisons among data from the doses of 0.1, 0.5 and 1.0 μg)
and treatment (comparisons among the SAL–SAL, SAL–HA, HA–SAL
and HA–HA groups). Duncan's post hoc test was conducted on the sta-
tistically signiﬁcant F values. A probability level of less than or equal to
0.05 was accepted as signiﬁcant.
All mice identically treated before trial 1 in the IA as well as in the
EPM with SAL or the different doses of HA exhibited no statistically
signiﬁcant differences among their measurements (one-way ANOVA,
p N 0.05). Thus, these mice were maintained in distinct groups on the
ﬁrst day to enable separate comparisons according to subsequent treat-
ment 24 h later.
3. Results
Fig. 2 represents the microinjection sites that were considered
successful. In this study, we did not consider speciﬁc amygdala
Fig. 3. Amnesic effect of histamine — tested with the doses 0.1, 0.5 and 1.0 μg/0.1 μl per
side — bilaterally microinjected into the mouse amygdala on inhibitory avoidance
memory. Columns represent means ± SEM of the latencies obtained from analyzed
mice: [a] SAL–SAL (n = 9), SAL–HA 0.1 (n = 10), HA 0.1–SAL (n = 8) and HA–HA0.1
(n = 9); [b] SAL–SAL (n = 9), SAL–HA 0.5 (n = 10), HA 0.5–SAL (n = 10) and HA–HA
0.5 (n = 9); [c] SAL–SAL (n = 8), SAL–HA 1.0 (n = 8), HA 1.0–SAL (n = 8) and HA–HA
1.0 (n = 7). ap ≤ 0.05 retention test compared with trial 1, bp ≤ 0.05 retention test
compared with trial 2, cp ≤ 0.05 trial 2 compared with trial 1. HA histamine; SAL saline.
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of the drug diffusion.
3.1. Intra-amygdala HA microinjected before testing impairs the fear
memory retrieval of mice in the inhibitory avoidance task
The number of mice per group that received one or two foot shocks
is described in Table 2. According to the sample, on average, 19.43 ±
4.06% of the tested mice did not enter the dark compartment during
trial 2, which suggests successful learning in the ﬁrst trial. However,
the majority of the tested mice required two foot shocks to learn fear
conditioning; all animals that received one or two shocks were tested
for retention 24 h later.
Repeated measures three-way ANOVA revealed signiﬁcant differ-
ences between the sessions F(2186)=80.76 (p b 0.01) and a signiﬁcant
interaction between the session and treatment factors F(6186) = 2.30
(p=0.04). Duncan's post hoc test detected that the retention test laten-
cy increased in the four groups of 0.1 μg HA related to trial 1: SAL–SAL
(p b 0.01), SAL–HA 0.1 (p b 0.01), HA 0.1–SAL (p b 0.01) and HA–HA
0.1 (p b 0.01) (Fig. 3a). Furthermore, the trial 2 latency of the HA–HA
0.1 mice signiﬁcantly increased compared with trial 1 latency (p =
0.02); this increase in the trial 2 latency was not evident for the HA
0.1–SAL group (p = 0.11), whose mice received the same drug and
dose before trial 1.
Signiﬁcant differences between sessions were also observed for the
performance of mice microinjected with HA 0.5 μg. Post hoc analysis
revealed that the retention test latency of SAL–SAL (p b 0.01), HA 0.5–
SAL (p b 0.01) and HA–HA 0.5 (p b 0.01) increased when compared
with trial 1 latency (Fig. 3b). Equal rising latencies were observed in
the retention test compared with the respective latency in trial 2
[SAL–SAL (p b 0.01), HA 0.5–SAL (p = 0.02) and HA–HA 0.5 (p b 0.01)].
Duncan's test pointed to signiﬁcant differences for the performed
latencies of microinjected rodents with 1.0 μg HA (Fig. 3c). Latency on
the retention test was greater than in trial 1 for the groups SAL–SAL
(p b 0.01), HA 1.0–SAL (p b 0.01) and HA–HA 1.0 (p b 0.01) and greater
than in trial 2 for the same groups, SAL–SAL (p = 0.03), HA 1.0–SAL
(p = 0.01) and HA–HA 0.1 (p = 0.02). Mice in the SAL–HA groups
treated with HA intra-amygdala at the 0.5 and 1.0 μg doses did not
have signiﬁcantly higher latencies on the retention test than trials 1
and 2 (p N 0.05).
In addition to the absence of a difference with treatment F(3,93) =
2.16 (p = 0.1) as a single variable, a difference for the interaction be-
tween session and treatment is indicated by the three-way ANOVA
F(6186) = 2.30 (p = 0.04). Duncan's test identiﬁed higher latencies
during the retention test in the control (p b 0.01), HA 0.5–SAL (p =
0.01) and HA–HA 0.5 (p b 0.01) groups than in the SAL–HA 0.5
(Fig. 3b). Furthermore, on retention latencies, thismeasurewas also sig-
niﬁcantly increased in the control (p=0.04), HA 1.0–SAL (p b 0.01) and
HA–HA 1.0 (p = 0.03) groups than in the SAL–HA 1.0 (Fig. 3c). These
differences among treatment groups during the test are not shown in
the graphic representation. These results suggest that the experimental
groups treated with vehicle pre-trial 1 and HA at the doses of 0.5 or
1.0 μg pre-test did not evoke aversive memory.Table 2
Number of mice per group that received one or two foot shocks during the two-trial
learning of the inhibitory avoidance task.
Number of mice that received
1 ft shock 2 ft shocks
Inhibitory avoidance group 0.1 μg 0.5 μg 1.0 μg 0.1 μg 0.5 μg 1.0 μg
SAL–SAL 2 2 1 7 7 7
SAL–HA 1 4 0 9 6 8
HA–SAL 1 3 2 7 7 6
HA–HA 4 0 1 5 9 6
HA: histamine; SAL: saline.3.2. Intra-amygdala HA microinjected before testing does not affect
the anxiety-like behavior and emotional memory of mice in the elevated
plus-maze
Enclosed arm entries (EAE) are considered a locomotor activity
measurement in the EPM (Fig. 4a, d, g). In addition to the absence of
an interaction difference, the three-way ANOVA revealed a signiﬁcant
difference for dose F(2,83) = 5.46 p b 0.01 in EAEmeasurement during
T1. Duncan's test identiﬁed a signiﬁcant decrease in the EAE frequency
during T1 in the HA 1.0–SAL group compared with control (p = 0.02)
and SAL–HA 0.5 (p = 0.05) — both groups from the intermediate
Fig. 4. Anxiolytic-like effect of histamine (0.5 μg/0.1 μl per side) bilaterally microinjected into the mouse amygdala, but its three doses (0.1, 0.5 and 1.0 μg/0.1 μl per side) do not affect
emotional memory. Columns represent means ± SEM from (a, d and g) frequency of enclosed arm entries (EAE), (b, e and h) the percentage of open arm entries (%OAE) and (c, f and
i) the percentage of time spent in open arms (%OAT) [SAL–SAL (n = 7), SAL–HA 0.1 (n = 9), HA 0.1–SAL (n = 7) and HA–HA 0.1 (n = 7); SAL–SAL (n = 10), SAL–HA 0.5 (n = 9),
HA 0.5–SAL (n = 9) and HA–HA 0.5 (n = 8); SAL–SAL (n = 9), SAL–HA 1.0 (n = 7), HA 1.0–SAL (n = 6) and HA–HA 1.0 (n = 7)]. p ≤ 0.05 aT2 compared with T1; bcompared with
SAL–SAL 0.5 in T1; ccompared with SAL–HA 0.5 in T1; dcompared with SAL–SAL 0.1 in T1; ecompared with SAL–HA 0.1 in T1; fcompared with HA–HA 0.1 in T1; gcompared with SAL–
HA 1.0 in T1. HA histamine; SAL saline; T1 trial 1; T2 trial 2.
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(p = 0.03), HA 1.0–SAL (p = 0.03) and HA–HA 1.0 (p = 0.02) of the
highest dose compared with HA 0.1–SAL mice of the lower dose and
compared with SAL–SAL of the intermediate dose.
Total entries (TE) were also analyzed tentatively to clarify the
general locomotion results (Table 3). According to ANOVA, there was
an interaction between session and treatment F(3,83) = 2.83 (p =
0.04) and a signiﬁcant difference between T1 and T2 F(1,83) = 17.42
(p b 0.01). This suggests that the TE data from the ﬁrst and second test-
ing days are inﬂuenced by HA injections. Post hoc analysis reveals that
the SAL–HA 1.0 (p b 0.01) and HA–HA 1.0 (p = 0.03) mice present
lower TE during re-exposure than in T1. Taken together, the doseTable 3
Conventionalmeasurements of themicewith histamine (HA0.1, 0.5 and 1.0 μg/0.1 μl per side) o
mean ± SEM from frequency of enclosed arm entries (EAE) and total entries (TE) during T1 a
Variable Control
SAL/T1 SAL/T2 SAL/T1 HA 0
Total entries (TE) 15.57 ± 3.32 13.14 ± 3.26 12.67 ± 1.99 11.67 ±
SAL/T1 SAL/T2 SAL/T1 HA 0
17.20 ± 1.12 14.00 ± 2.46 15.56 ± 1.66 10.56 ±
SAL/T1 SAL/T2 SAL/T1 HA 1
16.11 ± 1.20 11.33 ± 2.03 14.43 ± 1.32 7.29 ±
a p ≤ 0.05 compared with T1.difference for EAE in T1 and the interaction between session and treat-
ment for TE of 1.0 μgHAsuggest a tendency of locomotor hypoactivity in
mice treated with the highest dose of HA; not all animals identically
treated with the highest dose exhibited these differences.
Regarding the measurements of anxiety-like responses, three-way
ANOVA did not reveal a signiﬁcant difference for the %OAE comparisons
for dose, treatment or interactions in themicroinjected groups with HA
0.1 μg, 0.5 μg and 1.0 μg (p N 0.05). ANOVA applied to the %OAE of tested
groups indicated a signiﬁcant difference between T1 and T2 F(1,83) =
42.68 (p b 0.01). This difference for %OAE between exposure and re-
exposure was described by Duncan's post hoc test in mice treated
with SAL–SAL (controls of the lowest, p = 0.01, and highest doses,r vehicle (SAL)microinjected into the amygdala and analyzed in the EPM.Values represent
nd T2.
Treatment
.1/T2 HA 0.1/T1 SAL/T2 HA 0.1/T1 HA 0.1/T2
0.85 15.00 ± 2.62 15.57 ± 2.84 12.43 ± 1.09 10.86 ± 1.16
.5/T2 HA 0.5/T1 SAL/T2 HA 0.5/T1 HA 0.5/T2
1.84 11.89 ± 2.19 12.89 ± 2.03 11.38 ± 0.96 10.25 ± 2.44
.0/T2 HA 1.0/T1 SAL/T2 HA 1.0/T1 HA 1.0/T2
1.66a 9.33 ± 1.93 9.00 ± 3.51 11.71 ± 2.17 6.29 ± 1.54a
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Fig. 4b, e and h presents the signiﬁcant decreases in %OAE during the
re-exposure compared with the exposure values.
According to ANOVA, there is a marked interaction between session
and treatment factors F(3,83)=3.73 (p=0.01) for the %OAT during T1,
although no signiﬁcant difference for treatment was revealed. Duncan's
test (Fig. 4e) points to the elevated %OAT during T1 for the HA 0.5–SAL
group comparedwith the control (p=0.02) and SAL–HA0.5 (p=0.04)
groups.
Three-wayANOVA also detected an interaction between session and
dose F(2,83) = 6.29 (p b 0.01) on the %OAT. Signiﬁcant differences
regarding dose F(2,83) = 3.02 (p = 0.05) and testing days F(1,83) =
196.95 (p b 0.01) were revealed by ANOVA. For the exposure analysis,
post hoc test indicated that HA 0.5–SAL (p b 0.01) and HA–HA 0.5
(p=0.04) exhibitedmore time spent in the open arms than the control
group from the HA 0.1-μg experiment. Furthermore, HA 0.5–SAL
mice had an increased %OAT in T1 compared with the SAL–HA 0.1
(p b 0.01), HA–HA 0.1 (p b 0.01) and SAL–HA 1.0 (p = 0.02). Thus,
there was a tendency toward an anxiolytic action of HA at the dose
of 0.5 μg because the drug altered %OAT without changes in %OAE
measurement.
Regarding the %OAT measurements, decreased re-exposure re-
sponses in T2 related to T1 were identiﬁed for the following groups by
Duncan's post hoc test: mice treated with HA 0.1 μg [SAL–HA 0.1
(p = 0.02), HA 0.1–SAL (p b 0.01) and HA–HA 0.1 (p = 0.03)]
(Fig. 4c); mice treated with HA 0.5 μg [control (p b 0.01), SAL–HA 0.5
(p b 0.01), HA 0.5–SAL (p b 0.01) and HA–HA 0.5 (p b 0.01)] (Fig. 4f);
and mice treated with HA 1.0 μg [control (p b 0.01), SAL–HA 1.0
(p b 0.01), HA 1.0–SAL (p b 0.01) and HA–HA 1.0 (p b 0.01)] (Fig. 4i).
Considering the reductions in %OAE of some groups and %OAT in
most groups during the retest, HA microinjection into the mouse
amygdala was not able to modify the mnemonic processes examined
in the EPM.
4. Discussion
The inspection of brain sections conﬁrmed the microinjection sites
in the amygdala. We could not establish a correspondence between
behavioral responses and the excitation of speciﬁc sub-nuclei or
antero-posterior divisions due to the great proximity of the neuronal
groups on a sub-nuclei level. However, it is well known that CEA is a
neural nucleus that mediates amygdaloid outputs (Orsini and Maren,
2012), strongly related to contextual fear and memory formation
(Zimmerman and Maren, 2010), besides the associative function of
the external stimulus of threatening or learning under stressful condi-
tions mediated by BLA neuronal networks (McGaugh, 2004; Orsini
andMaren, 2012). BLA and CEAwere themain sites of themouse amyg-
dala where exogenous HA was infused in this study.
The time interval (5 to 14 min) between the microinjection and the
test in the IA and in the EPMwas appropriated to stimulate amygdaloid
activity. Exogenous HA could inﬂuence the behavioral responses exhib-
ited by the mice during the experiments because the apparent half-life
of this modulatory neurotransmitter in the brain is approximately
20 min (Schwartz et al., 1986).
4.1. Intra-amygdala HA microinjected before testing impairs the fear
memory retrieval of mice in the inhibitory avoidance task
In the IA task, the animal learns to associate the apparatus context,
which is not initially aversive, to an electric foot shock (Cahill and
McGaugh, 1998). During the trial, rodents experience the pairing of a
prior neutral stimulus, the posterior conditioned stimulus (CS), which
is composed of the dark compartment context and its entry, with an
unconditioned stimulus (US), the foot shock (Blake et al., 2008). In a
subsequent trial, these animals avoid the black compartment due
to the inhibition of innate mouse behavior, which is to look for darkburrows. Fear elicited by exposure to a cue or context associated with
foot shock is a phenomenon called fear conditioning (Gross and
Canteras, 2012). Robust avoidance responses exist because of fear and
have critical functions to individual survival, such as protection against
a potentially threatening environment (Fendt and Fenselow, 1999).
HAmicroinjections at 0.5 and 1.0 μg into the amygdala before the re-
tention test impairmemory retrieval, as observed in decreased latencies
for SAL–HA 0.5 and SAL–HA 1.0 mice. The amnesic effect is indicated by
the comparison among the lower test latencies of those groups, in rela-
tion to its respective trial latency, and the higher test latencies of control
and HA–HA mice. These latter groups exhibit fear conditioning, which
is inferred from increased retention latencies. Thus, intra-amygdala
administration of HA blocks the evocation of aversive information
acquired with endogenous histaminergic levels. The present result is
supported by the drug's inﬂuence on sessions according to ANOVA
interaction. It is unlikely that HA impaired the acquisition because
there was no difference between the saline- and HA-treated groups in
trials 1 and 2.
Former studies have also demonstrated the inhibitory role of HA on
the consolidation phase through H1 or H2 subtypes. Rats microinjected
i.c.v. with HA after a one-trial step-through exhibited an impairment
of memory retention; this deﬁcit was attenuated by pyrilamine (H1-
blocker) and cimetidine (H2-blocker) (Zarrindast et al., 2002). On H1
receptors, Hasenhörl et al. (2001) suggested a retention improvement
by chlorpheniramine infusions into the nucleus accumbens in rats
examined on the uphill avoidance test. Hence, blocking histaminergic
neurotransmission via H1 receptors could result in facilitation of the
mnemonic process.
Neuromodulatory interactions in the amygdala, as experimentally
reported and discussed by McGaugh (2004), have a crucial role in
emotional memory processing, not only in the BLA but also in the CEA
(Orsini and Maren, 2012; Zimmerman and Maren, 2010). We suggest
that theHAmodulation of the intrinsic cholinergic and/or glutamatergic
neurotransmission in BLA and CEA nuclei may justify the amnesic
effect observed. Exogenous HA would increase its availability in the
amygdaloid network; the action of H1 and H2 receptors would inhibit
acetylcholine (ACh) release in such a way as to disturb the local
neuroplasticity and to cause a memory deﬁcit for the mice tested.
Passani et al. (2001) treated rats with different H3-antagonists intra-
BLA in the post-trial of contextual fear and veriﬁed a reduction in ACh
release that compromised memory retention. Additionally, the highest
doses of HA could activate the H3 auto- and heteroreceptor in gluta-
matergic neurons, which composemost of the amygdala (approximately
80%) and underlie synaptic plasticity (Sah et al., 2003), promoting a
negative feedback and reducing the action of glutamatergic receptors
on long-term potentiation (LTP).
In the present study, HA at 0.5 or 1.0 μg increases the neurotransmit-
ter concentration at the amygdala,which affects the excitatory synapses
during aversive event retrieval. These physiologically disturbed concen-
trations could correspond to a pathological HA release, which destabi-
lizes the transmission and impairs the mice's ability to remember the
shock experience. Therefore, HA and its receptor(s) activation may be
tonically involved in very speciﬁc aspects of fear and anxiety behaviors
during aversive re-exposure. A high HA level may mimic the effects of
anxiolytic stimuli in the EPM and impair the IA retrieval.
4.2. Intra-amygdala HA microinjected before testing induces an
anxiolytic-like effect but does not affect the emotional memory of mice in
the elevated plus-maze
The EPM has been traditionally used to investigate anxiety-like be-
haviors and, most recently, emotional memory. Evidence has conﬁrmed
that a rodent's previous experience in this apparatus modiﬁes subse-
quent reactions to the same test (Holmes and Rodgers, 1998; Rodgers
et al., 1996). Thus, there is a qualitative modiﬁcation of the emotional
status that changes from an unconditioned (T1) to a learned form
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anxiety evaluation in T1 and fear behaviors observed in T2. Mice
that are experienced with the EPM will exhibit an elevated avoidance
of the potentially dangerous arms of themaze based on their thigmotaxis
and vision.
The dose of 0.5 μg HA into the amygdala elevates the conventional
measure of %OAT during T1, which could be clearly observed in the
HA 0.5–SAL mice and, to a lesser extent, in HA–HA 0.5, suggesting an
anxiolytic-like effect on murine exploration. This anxiolysis does not
occur due to any motor alterations because the treatment does not
alter the number of entries into the enclosed arms of the EPM or the
total frequency of entries during T1. However, the EAE measurement
in T1 is reduced in mice treated with the highest dose (HA 1.0–SAL
group), which indicates a tendency of locomotor activity impairment,
even though it does not occur for HA–HA 1.0 animals.
Studies have already shown a histaminergic modulation of anxiety
examined in the EPM and in other models with pharmacological as
well as genotype manipulations. HA administration into the hippocam-
pal CA1 of rats, a limbic area that underlies the defensive response, pro-
voked an anxiolytic effect assessed in the EPM (Zarrindast et al., 2006).
Knockout of the H3 receptor produced reduced anxiety-like behaviors
related to the wild-type controls in the EPM and in the elevated zero
maze, likely due to an increased release of HA and subsequent stimula-
tion of the other histaminergic receptors (Risk et al., 2004).
In contrast, intra-amygdala administration of HA induced
anxiogenic-like effects in rats examined in the EPM exposure, while
the H1-antagonist pyrilamine administration provoked anxiolytic
effects (Moghaddam et al., 2008) and reversion of the anxiogenesis
(Zarrindast et al., 2005). Benetti and Izquierdo (2013) suggested that
intra-amygdala administration of HA, agonists and antagonists for
distinct histaminergic receptors in rats 24 h before the test did not inﬂu-
ence the performance during the exposure in the EPM. Those ﬁndings
suggest that the role of HNS on anxiety-like responses depends on the
action of a speciﬁc receptor and subject.
According to the test/retest paradigm, the present results suggest a
decreased exploration of the unprotected areas in T2, as well as the nat-
ural condition; that is, there are no effects of intra-amygdala HA on the
emotionalmemory ofmice subjected to the EPM. TheOAE of the control
and the groups treatedwith HA0.5 or 1.0 μg pre-T2 and treatedwithHA
1.0 before the two tests decreased signiﬁcantly during the re-exposure,
compared with the respective exposure. A similar reduction was ob-
served for %OAE in T2 of the groups at the lowest dose. However, the
number of entries was less indicative of avoidance than the time in
the open arms; we considered the signiﬁcant reductions in OAT and
%OAT and important increases in CAT in T2 as decisive measures to es-
tablish successful learning and memorization of the aversive context.
Therefore, in the present study, the effects of HA microinjection into
the mouse amygdala are absent in the T1/T2 paradigm.
4.3. Comparison between Experiment 1 and Experiment 2
The two experimental models used in this study evaluated the aver-
sivememory ofmice but in the following distinct behavioral paradigms:
the EPM is based on the innate avoidance of potentially threatening
areas acquired on the ﬁrst test, and the IA is based on the conditioned
avoidance to a real danger and is related to fear expression. Aversive-
ness memory is modulated by more than one neuroanatomical system
with different HA amounts operating on each one of these pathways,
as reported by Fiorenza and colleagues (2012) for the extinction stage
in fear-motivated tasks, contextual conditioned fear and IA.
Distinct neural systems control the categories of emotion,
e.g., anxiety and fear. The circuit associated with the unconditioned de-
fensive response is known as the aversive brain system (ABS) (Brandão
et al., 1999, 2003), whereas the learned behavior is arranged by the
behavioral inhibition system (BIS) (Gray and McNaughton, 2000). Sim-
ilar to an interface between sensations and emotions, the amygdaloidcomplex seems to be involved in both systems (LeDoux, 2000), process-
ing the information through an intrinsic network (intra and inter-
nuclear projections) according to the interactionswith other integrative
areas of sensitive inputs (Sah et al., 2003). The BLA would be the local
host for critical interactions among neuromodulator systems that regu-
late extrinsic mnemonic processes of various experiences (Davis et al.,
2003); one of these modulator systems could be the HNS (Jiang et al.,
2005; McGaugh, 2004).
McNaughton and Corr (2004) proposed the existence of functional,
behavioral and pharmacological distinctions between anxiety and fear.
Fear would move the animal away from a dangerous source; fear
induces ﬁght, ﬂight and freezing behaviors. In contrast, anxiety occurs
in an approach-avoidance conﬂict tomove the animal toward the threat
source; anxiety induces the inhibition of approach and avoidance,
increases the risk assessment and produces defensive quiescence. The
equivalent and concurrent activation of the ABS and approach systems
creates an anxiety status, along with an importantly parallel participa-
tion of the BIS in the expression of risk access postures and elevated
aversion during conﬂict situations (Gray and McNaughton, 2000;
McNaughton and Corr, 2004). The HNS could promote an important
mechanism to reﬁne an appropriated behavioral response processed
by the amygdala (Benetti and Izquierdo, 2013).
Our research group previously showed that the cerebellar histamin-
ergic system is involved in the consolidation stage differently when the
emotional memory has an anxiety component (EPM) (Gianlorenço,
Canto-de-Souza and Mattioli, 2011) or a fear component (IA)
(Gianlorenço, Canto-de-Souza and Mattioli, 2013). Considering that
two different emotional systems — the ABS and BIS — are involved in
anxiety and fear learning, we suggest that the histaminergic neurons
in the amygdala modulate these emotional circuitries in different
ways. HA is involved in memory disruption, which is linked to aging,
e.g., Alzheimer's disease (Alvarez et al., 1996; Passani and Blandina,
2011). Thus, these present ﬁndings contribute to the biological basis
of investigation for learning and memory and, consequently, to a better
comprehension of emotional and mnemonic disorders.
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